Application of liquid chromatography in defining the interaction of newly synthesized chalcones and related compounds with human serum albumin Scientific paper

Abstract

Defining the interaction of newly synthesized compounds with plasma proteins is an important step in the drug development process. Chroma­tographic techniques can be successfully used in predicting the biopharma­ceut­ical and pharmacokinetic properties of newly synthesized compounds. The aim of this study is to investigate and isolate the most important molecular pro­perties that affect the interaction of 20 newly synthesized chalcones and com­mercial compounds (lopinavir, ritonavir, darunavir and ivermectin) with human serum albumin (HSA). The retention behaviour of the selected compounds was tested on a CHIRALPAK®HSA column. A mixture of phosphate buffer (pH 7.0) and isopropanol (80:20 volume ratio) was used as the mobile phase, and the support vector method was used to form the quantitative structure retention relationship (QSRR) model. Based on the obtained values of retention para­meters, it was observed that halogenated der­ivat­ives show the strongest, and methylated chalcone derivatives the weakest interaction with HSA. By correl­ating the retention and physicochemical pro­perties of the tested compounds, it was shown that the structural (SDSCH) and electronic properties (MAXQ, EEM_F1) groups have the greatest influence on the retention behaviour and the interaction of the tested compounds with HSA. The obtained QSRR model can be applied in the prediction of the retention characteristics of new, structurally related chalcone derivatives on HSA stationary phase.